The supplied market analysis estimates ... having a genetic component and a significant proportion involving pediatric onset. Neurological disorders represent an important category within the rare-disease landscape, while oncology, hematology, metabolic disorders, pulmonary diseases, and other therapeutic areas are also attracting substantial research attention. The orphan drugs industry is evolving alongside advances in genomics, molecular biology, cell therapy, and ... The supplied market analysis estimates that approximately 6,000 to 8,000 rare diseases have been identified, with around 80% having a genetic component and a significant proportion involving pediatric onset. Neurological disorders represent an important category within the rare-disease landscape, while oncology, hematology, metabolic disorders, pulmonary diseases, and other therapeutic areas are also attracting substantial research attention. The orphan drugs industry is evolving alongside advances in genomics, molecular biology, cell therapy, and precision medicine. Pharmaceutical and biotechnology companies are expanding pipelines targeting rare cancers, neurological disorders, hematological diseases, genetic conditions, and metabolic disorders. Advances in genomics, cell therapy, gene-editing technologies, and biologics are broadening the scientific basis for developing treatments for conditions that previously had limited therapeutic options. The global orphan drugs market was valued at approximately US 195 0 billion in 2023 and is projected to grow at a CAGR of 6 9 from 2024 to 2034 reaching approximately US 424 0 billion by the end of ... Press release - Transparency Market Research - Orphan Drugs Market to Reach US$424.0 Billion by 2034 Amid Rising Rare Disease Burden and R&D Investments - TMR - published on openPR.com

A new study highlights respiratory manifestations as potential indicators for inherited metabolic disorders in children, advocating for a phenotype-driven diagnostic approach. This research could enhance early detection and treatment strategies for these rare conditions.

Ultragenyx Pharmaceutical received ... storage disease type Ia (GSDIa), the company announced on August 19, 2026.1 The approval marks the company's fifth FDA approval and its first for a gene therapy product. GSDIa is an ultra-rare, inherited metabolic disorder caused by pathogenic ... Ultragenyx Pharmaceutical received accelerated approval from the FDA for Genglycos (pariglasgene brecaparvovec-opnr), a gene therapy for adult and pediatric patients 8 years and older with glycogen storage disease type Ia (GSDIa), the company announced on August 19, 2026.1 The approval marks the company's fifth FDA approval and its first for a gene therapy product. GSDIa is an ultra-rare, inherited metabolic disorder caused by pathogenic variants in the gene encoding glucose-6-phosphatase, an enzyme needed to release glucose from the liver into the bloodstream.1 Without it, patients face a constant risk of severe, potentially life-threatening low blood sugar and must follow an around-the-clock regimen of raw cornstarch intake to maintain stable glucose levels. The FDA grants accelerated approval to Ultragenyx's Genglycos, the first gene therapy for GSDIa, raising manufacturing and post-market monitoring questions. The therapy also carries a boxed set of warnings common to adeno-associated virus vector gene therapies, including hypersensitivity reactions, immune-mediated liver toxicity, and adrenal insufficiency tied to the corticosteroid regimen used to manage hepatic reactions.1 Distribution will run through a national network of qualified treatment centers trained to administer the therapy, an access model increasingly used for specialized cell and gene therapy products that require infusion oversight and long-term patient monitoring beyond what a typical infusion center provides. “As our first gene therapy approval, Genglycos represents an important achievement for our company and the realization of the promise of a powerful new tool to deliver transformative medicines for people living with rare diseases,” said Eric Crombez, MD, chief medical officer, Ultragenyx, in the press release.1 That structure illustrates how sponsors of ultra-rare disease gene therapies are increasingly relying on long-term, real-world monitoring to satisfy regulators when trial populations are too small to generate conventional statistical power.

Shares of Ultragenyx Pharmaceutical RARE are rising in premarket trading today following the FDA’s accelerated approval of DTX-401, an AAV8 gene therapy for glycogen storage disease type Ia (GSDIa).The therapy will be marketed in the United States as Genglycos (pariglasgene brecaparvovec-opnr) ... Shares of Ultragenyx Pharmaceutical RARE are rising in premarket trading today following the FDA’s accelerated approval of DTX-401, an AAV8 gene therapy for glycogen storage disease type Ia (GSDIa).The therapy will be marketed in the United States as Genglycos (pariglasgene brecaparvovec-opnr) and… GSDIa is an ultra-rare inherited metabolic disorder caused by pathogenic variants in the G6PC gene. These variants lead to a deficiency of glucose-6-phosphatase, an enzyme required for the release of glucose from stored glycogen and other metabolic sources. Even with strict adherence, interruptions in treatment can expose patients to severe hypoglycemia, seizures and potentially life-threatening complications, making the disease particularly burdensome for patients and caregivers. Against this backdrop, the FDA decision is significant because Ultragenyx’s Genglycos is designed to address the underlying biological defect in GSDIa rather than manage its metabolic consequences. By delivering a functional G6PC gene to the liver, the therapy aims to restore the enzyme’s role in glucose production during fasting or metabolic stress, potentially reducing patients’ reliance on intensive cornstarch supplementation and easing the day-to-day burden of glucose management. The therapy will be marketed in the United States as Genglycos (pariglasgene brecaparvovec-opnr) and is indicated to reduce daily cornstarch intake as an adjunct to nutritional management in adult and pediatric patients aged eight years and older with GSDIa. The approval makes Genglycos the first FDA-approved treatment designed to address the underlying cause of GSDIa and marks Ultragenyx’s first gene therapy approval and its fifth FDA approval overall. FDA Nod for RARE’s Genglycos Supported by Phase III Data

Four IPOs are currently scheduled for the week ahead, featuring three biotechs and a California bank. Four IPOs are currently scheduled for the week ahead, featuring three biotechs and a California bank. - Renaissance Capital Four IPOs are currently scheduled for the week ahead, featuring three biotechs and a California bank. Mega-issuer SpaceX (SPCX) will also be in focus as it reports earnings for the first time as a public company ahead of a partial lock-up release that will more than double the tradable float. Cardiovascular disease biotech Braveheart Bio (BRVE) is set to raise $300 million at a $1.4 billion market cap. Immune system-focused biotech Attovia Therapeutics (ATTO) plans to raise $200 million at a $649 million market cap. Attovia is developing biologic therapies for immune-mediated diseases using its ATTOBODY platform to create next-generation antibody therapeutics targeting validated immune pathways. Its commercial real estate lending franchise accounted for roughly 90% of its loan portfolio as of June 30, 2026. River City has also developed a niche serving California Community Choice Aggregator entities, although the resulting deposit base is fairly concentrated. Metabolic disorder biotech Vogenx (VOGX) plans to raise $75 million at a $173 million market cap.